Compare Ascendis Pharma A/S (ASND) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Global X Robo Global Robotics & Automation ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Global X Robo Global Robotics & Automation ETF trades at $81.56. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ASND | ROBO | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $90.34 |
52-Week Low | $163.32 | $60.15 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ROBO trades at $82.96, up 0.45% today, but technical indicators signal a bearish trend with selling pressure outweighing buying signals. The stock faces resistance near $83 with support at $79. Recent news highlights the ETF's rebalancing toward AI infrastructure and physical automation, positioning it for the expanding robotics market. Financial ratios remain undisclosed, requiring deeper fundamental review.
Outlook is cautious due to bearish technicals and cyclical exposure, but long-term potential exists in AI-driven automation. Risks include market volatility and competition, while institutional interest in thematic ETFs may provide support. Investors should weigh near-term headwinds against secular growth in robotics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
